3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
2
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
7
Pain, Postoperative
5
Leiomyoma
3
Carcinoma, Hepatocellular
3
Stomatitis
2
Pituitary Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Chronic Pain
2
Uterine Cervical Neoplasms
1
Ulcer
1
Supratentorial Neoplasms
1
Sleep Wake Disorders
1
Rhabdomyosarcoma, Alveolar
1
Retinoblastoma
1
Rectal Neoplasms
1
Pulmonary Atelectasis
1
Pleural Effusion, Malignant
1
Pituitary Diseases
1
Phlebitis
1
Peripheral Nervous System Diseases
1
Patient Participation
1
Pancreatic Ductal Adenocarcinoma
1
Non-functioning Pituitary Adenoma
1
Neurotoxicity Syndromes
1
Neuralgia
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Interventions
Dexamethasone
64
Cyclophosphamide
40
Bortezomib
37
Melphalan
24
Lenalidomide
23
Thalidomide
17
pomalidomide
16
fludarabine
12
daratumumab
11
carfilzomib
10
Filgrastim
8
Doxorubicin
8
Busulfan
6
Prednisone
5
Peripheral Blood Stem Cell Transplantation
5
Bendamustine Hydrochloride
5
selinexor
4
sargramostim
4
isatuximab
4
fludarabine phosphate
4
Surveys and Questionnaires
4
Etoposide
4
Clarithromycin
4
Calcium Dobesilate
4
liposomal doxorubicin
3
ixazomib
3
Radiotherapy
3
Neoadjuvant Therapy
3
Mycophenolic Acid
3
Methylprednisolone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Multiple Myeloma
×
Saline Solution
×
Clear all
NCT05493800
2024-05-29
Capella
MitoImmune Therapeutics
Phase 2
Unknown
60 enrolled